F
Fiona M. Gribble
Researcher at University of Cambridge
Publications - 294
Citations - 29716
Fiona M. Gribble is an academic researcher from University of Cambridge. The author has contributed to research in topics: Enteroendocrine cell & Insulin. The author has an hindex of 85, co-authored 273 publications receiving 24678 citations. Previous affiliations of Fiona M. Gribble include Wellcome Trust & University of Copenhagen.
Papers
More filters
Journal ArticleDOI
Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2
Gwen Tolhurst,Helen Heffron,Yu Shan Lam,Helen E. Parker,Abdella M. Habib,Eleftheria Diakogiannaki,Jennifer Cameron,Johannes Grosse,Frank Reimann,Fiona M. Gribble +9 more
TL;DR: It is shown here that SCFAs trigger secretion of the incretin hormone glucagon-like peptide (GLP)-1 from mixed colonic cultures in vitro and in vivo and a parallel impairment of glucose tolerance is observed in mice lacking ffar2 or ffar3.
Journal ArticleDOI
An SCN9A channelopathy causes congenital inability to experience pain
James J. Cox,Frank Reimann,Adeline K Nicholas,Gemma K. Thornton,Emma Roberts,Kelly Springell,G. Karbani,Hussain Jafri,Jovaria Mannan,Yasmin Raashid,Lihadh Al-Gazali,Henan Hamamy,Enza Maria Valente,Shaun Gorman,Richard Aled Williams,Duncan McHale,John N. Wood,Fiona M. Gribble,C. Geoffrey Woods +18 more
TL;DR: The data suggest that SCN9A is an essential and non-redundant requirement for nociception in humans, and should stimulate the search for novel analgesics that selectively target this sodium channel subunit.
Journal ArticleDOI
Truncation of Kir6.2 produces ATP-sensitive K + channels in the absence of the sulphonylurea receptor
TL;DR: It is shown that the primary site at which ATP acts to mediate K-ATP channel inhibition is located on Kir6.2, and that SUR1 is required for sensitivity to sulphonylureas and diazoxide and for activation by Mg-ADP.
Journal ArticleDOI
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard,Irina Hauselmann,Beat Schuler,Abdella M. Habib,Laurie L. Baggio,Daniel T. Meier,Elisabeth Eppler,Karim Bouzakri,Stephan Wueest,Yannick D. Muller,Ann Maria Kruse Hansen,Manfred Reinecke,Daniel Konrad,Max Gassmann,Frank Reimann,Philippe A. Halban,Jesper Gromada,Daniel J. Drucker,Fiona M. Gribble,Jan A. Ehses,Marc Y. Donath +20 more
TL;DR: Interleukin-6 mediates crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand and suggests that drugs modulating this loop may be useful in type 2 diabetes.
Journal ArticleDOI
Glucagon-like peptide 1 (GLP-1)
Timo D. Müller,Brian Finan,Stephen R. Bloom,David A. D'Alessio,Daniel J. Drucker,Peter R. Flatt,Andreas Fritsche,Fiona M. Gribble,Harvey J. Grill,Joel F. Habener,Jens J. Holst,Wolfgang Langhans,Juris J. Meier,Michael A. Nauck,Diego Perez-Tilve,Alessandro Pocai,Frank Reimann,Darleen A. Sandoval,Thue W. Schwartz,Randy J. Seeley,Kerstin Stemmer,Mads Tang-Christensen,Stephen C. Woods,Richard D. DiMarchi,M.H. Tschöp +24 more
TL;DR: The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.